Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis – (Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis, Published online: 2018-12-21; | doi:10.1038/s41433-018-0321-y)

21 December 2018

This news item is available to RCOphth members only, please log in below to access.